Scientists Test New Prostate Disease Drug
Posted on: Thursday, 27 March 2008, 15:00 CDT
A Canadian-headquartered biopharmaceutical company is conducting the second Phase 3 study of a new drug designed to treat prostate disease.
Aeterna Zentaris Inc. said the double-blind study to be conducted in Europe will test the clinical effectiveness of cetrorelix, a luteinizing hormone-releasing drug for the treatment of benign prostatic hyperplasia, or BPH -- a non-cancerous enlargement of the prostate that causes disturbances in urination.
In the second Phase 3 study, 400 male patients will enter a four-week, no-treatment observation period and then be randomly assigned to either receive cetrorelix or a placebo. Effectiveness will based on a test that measures the severity and stability of voiding prostate symptoms.
The company's first study of the effectiveness of cetrorelix began in April 2007 and is continuing in Canada, Europe and the United States.
Source: United Press International
Related Articles
- Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
- Six-Month Study Evaluated Effectiveness of Aripiprazole and Standard of Care In Management of Community-Treated Patients With Schizophrenia
- Study Questions Popular Prostate Treatment
- New Study Finds Certain Prostate Tests Don't Work To Reduce Deaths From Prostate Cancer
- Study into Effects of Mums' Diet on Children
- Homoeopathy Benefits Could Be All in the Patient's Mind Study Questions Effectiveness of Treatment
- RegeneRx Enters Research Collaboration to Study Protective Effects of TB4 on Degenerative Muscle Disease and Cardiomyopathy
- Study Backs Proactive Prostate Surgery Over Delayed Approach
- Study Links Cholesterol, Prostate Cancer
- Vitamin E Scare Hurts Cancer Trial; Doctors Say Their Study on Supplement, Prostate Cancer Prevention is Safe
 |
 |
User Comments (0)
RSS Feeds